drugset / Trial / NCT00447642

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642

Phase 3 Terminated 122 enrolled Lux Biosciences, Inc.
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an immune response.

Timeline

Start
2007-04
Primary completion
2008-08
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 30 % Other